Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA labs stay open

This article was originally published in The Tan Sheet

Executive Summary

House Energy and Commerce Chairman John Dingell says an Aug. 17 decision by FDA to not proceed with reorganization plans that include closing seven of its field labs will maintain an "essential part of protecting consumers and ensuring the safety of our nation's food and drug supply." FDA has called off plans to close seven of its 13 labs as part of the Office of Regulatory Affairs reorganization it announced in March, Dingell and fellow Michigan Democrat Bart Stupak, Oversight and Investigation Subcommittee chairman, say in a release (1"The Tan Sheet" March 26, 2007, p. 5). The House has passed legislation with FDA's fiscal 2008 appropriations with an amendment from Stupak that prohibits the agency from using any of the funding to pay for closing its field labs or ORA district offices...

You may also be interested in...

FDA To Close Regional Offices, Consolidate Districts Under ORA Reorg

FDA's decision to reorganize the Office of Regulatory Affairs will cause a "slow motion effect" for industry's interaction with FDA, according to a dietary supplement trade group executive

Teva Debuts US Azopt Rival

Teva has launched the first and so far only US generic version of Novartis’ Azopt treatment for ocular hypertension, with the brinzolamide 1% solution having been developed and manufactured by Indoco Remedies.

EU MDR Notified Body Designations Could Soar By A Third By End Of 2021

There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts